Abstract: AIM: To investigate the bioequivalence of lansoprazole enterosoluble tablets and capsules in Chi-nese healthy volunteers.METHODS: Twenty volunteers were randomly divided into two groups (test and refer-ence), with double cross over design.The concentration of lansoprazole in serum was determined by HPLC and pharmacokinetic parameters were calculatedwith DAS 2.0 practical pharmacokinetics program.RESULTS: The pharmacokinetic parameters of lansoprazole enterosoluble tablets and capsules were as follows:t_1/2 were 1.808 ± 1.031 and 1.341 ±0.498 h, C_max were 0.764 ±0.385 and 0.902 ±0.369 μg·ml^-1, T_max were 3.639 ±0.744 and 2.500±1.000 h, AUC 0-10h were 3.024±1.941 and 3.098±1.742 μg·h·ml^-1。 The relative bioavalibility of lansoprazole enterosoluble tablets was 109.57% ± 59.48%. CONCLUSION: The statistical analysis showed that the test and reference preparation were bio-equivalent.

Key words: lansoprazole, healthy human body, HPLC, bioequivalence